Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation

Atrial FibrillationFurther Publications

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Circ Arrhythm Electrophysiol

Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L

doi: 10.1161/CIRCEP.125.014101

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Atrial FibrillationThrombosis and Stroke

Sex Differences and 2-Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register-Based Study in Sweden

J Am Heart Assoc

Al Khatib I, Viktorisson A, Abzhandadze T, Sunnerhagen KS

doi: 10.1161/JAHA.124.037608

Atrial Fibrillation

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Clin Res Cardiol

Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D, START2 Register Investigators

doi: 10.1007/s00392-025-02765-7

Heart Failure

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Clin Res Cardiol

Ojeda-Fernández L, Torrigiani G, Molteni M, Fortino I, Cimminiello C, Baviera M

doi: 10.1007/s00392-025-02674-9

Atrial Fibrillation

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Cardiovasc Diabetol

Ryu H, Lee SR, Choi EK, Go YH, Lee KY, Choi J, Han S, Kim JH, Ahn HJ, Kwon S, Kim BS, Han KD, Oh S, Lip GYH

doi: 10.1186/s12933-025-02795-5

Atrial Fibrillation

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

Cardiovasc Diabetol

Meulendijks ER, Fabrizi B, Bruns S, Eringa EC, Hoebe R, van den Boogert T, Wesselink R, Al-Shama RFM, de Vries TAC, Ernault AC, Niessen HWM, van Boven WJP, Driessen AHG, Zbairi I, Zappala P, Dey D, Isgum I, Planken RN, Krul SPJ, de Groot JR

doi: 10.1186/s12933-025-02985-1

Hypertension

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)

Drugs Real World Outcomes

Escribano Subias P, Chakinala MM, Chin KM, Didden EM, Doad G, Farber HW, Gaine S, Hemnes AR, Highland KB, Lange TJ, McLaughlin V, Muller A, Rahman M, Remeňová T, Söderberg S, Venkatesh A, Kim NH

doi: 10.1007/s40801-025-00536-4

Atrial FibrillationHeart, Artery and Coronary Diseases

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial

JAMA Cardiol

Yamaguchi J, Arashi H, Hagiwara N, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Matsui K, Ogawa H, AFIRE Investigators

doi: 10.1001/jamacardio.2025.2611

Related content

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Sex Differences and 2-Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register-Based Study in Sweden

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial